Trevi prices $50M underwritten offering of 12.5M shares at $4.00 per share

Trevi Therapeutics, Inc.

Offering of 12.5M shares at $4.00/share; net proceeds ~$46.7M after underwriting discounts and expenses.
Participants include Adage Capital, Frazier Life Sciences, Logos Capital, MPM BioImpact, Rubric Capital, Vivo Capital.
Expected to close on December 17, 2024, subject to customary conditions.
Company developing Haduvio for chronic cough in IPF and refractory chronic cough.
Leerink Partners, Stifel, and Oppenheimer are joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.